Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes
Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
To investigate whether the Glucagon Like Peptide 1 (GLP-1) Semaglutide (1.34 mg/ml) has
preventive effect compared to placebo in the development of diabetes and Metabolic Syndrome
in people with pre-diabetes, overweight and schizophrenia, who receive antipsychotic
treatment.
Furthermore to investigate for an effect of Semaglutide compared to placebo on psychotic
symptoms and quality of life in people with schizophrenia, prediabetes and overweight.
Phase:
Phase 2
Details
Lead Sponsor:
Jan Frystyk
Collaborators:
Region of Southern Denmark Region Zealand Steno Diabetes Center Odense Steno Diabetes Center Sjaelland